2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
The need for novel c-Abl inhibitors
A protein called Abelson Tyrosine Kinase – or c-Abl – is believed to be involved in the biological processes leading to loss of dopamine neurons in the brains of people with Parkinson’s. In many preclinical studies, stopping the harmful c-Abl processes with the use of drugs called c-Abl inhibitors have found that c-Abl activity decreases….
Cell Replacement Therapy – TRANSEURO
TRANSEURO, involving a consortium of scientists led by Professor Roger Barker in Cambridge and funded in part by Cure Parkinson’s and the EU, has developed a clear pathway to use stem cells as a viable treatment for Parkinson’s, and is addressing the previously mismatched results…
Type 2 diabetes medications impact risk of Parkinson’s
In a recent study, researchers have concluded that the elevated risk of Parkinson’s in patients with type 2 diabetes might be mitigated depending on the type of drugs prescribed to treat this type of diabetes.
The 2020 International Linked Clinical Trials meeting
The International Linked Clinical Trials (iLCT) programme is the drug repurposing initiative focussed on identifying and clinically testing drugs that show potential in slowing or reversing the progression of Parkinson’s.
The John Black Charitable Foundation joins Cure Parkinson’s as Strategic funding partner
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to welcome a third strategic funding partner, The John Black Charitable Foundation (JBCF), to the International Linked Clinical Trials (iLCT) programme.